Targeted therapies for renal cell carcinoma: more gains from using them again

@inproceedings{Gan2009TargetedTF,
  title={Targeted therapies for renal cell carcinoma: more gains from using them again},
  author={H. K. Gan and Bo{\vs}tjan {\vS}eruga and J Knox},
  booktitle={Current oncology},
  year={2009}
}
The development of molecularly targeted agents that inhibit pathways critical to the development of renal cell carcinoma has significantly improved outcomes in patients with these cancers. Compelling scientific and phase iii data have made the use of molecularly targeted agents the standard of care in first-line treatment. Now, available data show that re-treating patients with other tyrosine kinase inhibitors after they progress on sunitinib or sorafenib, or both, is beneficial. A large phase… CONTINUE READING

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 51 references

A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccrcc) refractory to prior sunitinib or bevacizumab [abstract 346

  • BI Rini, TE Hutson, P Elson
  • Am Soc Clin Oncol Genitourin Cancers Symp 2008…
  • 2009

Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (rcc) refractory to sorafenib [abstract 5032

  • BI Rini, GT Wilding, G Hudes
  • Proc Am Soc Clin Oncol 2007;25:. [Available…
  • 2009

Cost of illness of renal cell carcinoma in Canada [abstract 15560

  • A Abugaber, K Lang, N Danchenko
  • Proc Am Soc Clin Oncol 2007;25:. [Available…
  • 2009

Phase ii study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (rcc) [abstract 5010

  • RC Whorf, JD Hainsworth, DR Spigel
  • Proc Am Soc Clin Oncol 2008;26:. [Available…
  • 2009

Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract 5038

  • MP Sablin, L Bouaita, C Balleyguier
  • Proc Am Soc Clin Oncol 2007;25:. [Available…
  • 2009

Sorafenib as a secondline and sequential therapy for patients with metastatic renal cell carcinoma (mrcc): analysis for safety and activity on sunitinib progressive pts [abstract 16100

  • J Sepulveda, P Maroto, R Andres
  • Proc Am Soc Clin Oncol 2008;26:. [Available…
  • 2009

Sunitinib in metastatic renal cell carcinoma (mrcc): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis [abstract 5010

  • ME Gore, C Porta, S Oudard
  • Proc Am Soc Clin Oncol 2007;25:. [Available…
  • 2009

The combination of sorafenib and vorinostat causes synergistic growth inhibition in kidney cancer cells [abstract 402

  • HA Drabkin
  • Am Soc Clin Oncol Genitourin Cancers Symp 2008…
  • 2009

on behalf of the arccs Investigators. The Advanced Renal Cell Carcinoma Sorafenib (arccs) expanded access trial in North America: safety and efficacy [abstract 5011

  • JJ Knox, RA Figlin, WM Stadler
  • Proc Am Soc Clin Oncol 2007;25:
  • 2009

Similar Papers

Loading similar papers…